Post-earnings recap
Reported
Wed, Nov 2, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Castle Biosciences reported a loss per share of $0.77, which was a 10% miss compared to expectations. The stock reacted negatively, declining by 4.07%. The lack of revenue figures and management commentary adds uncertainty about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.77 | N/A | -10.00% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.